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Abstract 
SIGNIFICANCE: A mismatch between energy supply and demand induces tissue hypoxia 
with the potential to cause cell death and organ failure. Whenever arterial oxygen 
concentration is reduced, increases in blood flow - ‘hypoxic vasodilation’ - occur in an 
attempt to restore oxygen supply. Nitric oxide is a major signalling and effector molecule 
mediating the body’s response to hypoxia, given its unique characteristics of vasodilation 
(improving blood flow and oxygen supply) and modulation of energetic metabolism (reducing 
oxygen consumption and promoting utilization of alternative pathways).  
RECENT ADVANCES: This review covers the role of oxygen in metabolism and responses 
to hypoxia, the hemodynamic and metabolic effects of nitric oxide, and mechanisms 
underlying the involvement of nitric oxide in hypoxic vasodilation. Recent insights into nitric 
oxide metabolism will be discussed, including the role for dietary intake of nitrate, 
endogenous nitrite reductases, and release of nitric oxide from storage pools. The 
processes through which nitric oxide levels are elevated during hypoxia are presented, 
namely (i) increased synthesis from nitric oxide synthases, increased reduction of nitrite to 
nitric oxide by heme- or pterin-based enzymes and increased release from nitric oxide 
stores, and (ii) reduced deactivation by mitochondrial cytochrome c oxidase.  
CRITICAL ISSUES: Several reviews covered modulation of energetic metabolism by nitric 
oxide, while here we highlight the crucial role NO plays in achieving cardiocirculatory 
homeostasis during acute hypoxia through both vasodilation and metabolic suppression 
FUTURE DIRECTIONS: We identify a key position for nitric oxide in the body’s adaptation to 
an acute energy supply-demand mismatch. 
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Introduction 
 
Patients undergoing major surgery or suffering critical illness have increased cellular energy 
demands yet commonly experience challenges in ensuring an adequate oxygen supply. An 
oxygen supply-demand imbalance can be immediately life-threatening, such as in cardiac 
arrest or major haemorrhage, or it may cause more insidious damage. As organ function is 
critically linked to both oxygen availability (30) and adequate utilization, bioenergetic 
deficiency is likely to be a crucial factor underlying the pathogenesis of cell death (39) and 
multiple organ failure (18,202). 
 
The main purpose of the cardiovascular system is to provide oxygen and metabolic 
substrates at a rate that can both meet and respond rapidly to changes in local demand. 
Whenever arterial oxygen concentration is reduced, increases in local blood flow - ‘hypoxic 
vasodilation’ - occur in an attempt to restore oxygen supply (102). The ability of hypoxia to 
increase tissue blood flow is a local response that can be demonstrated in isolated organs, 
thus it can occur without the involvement of neurally-mediated reflex mechanisms. A variety 
of mediators such as adenosine (22), ATP-sensitive potassium channels (65)  and 
prostaglandins (173) are implicated, however significant human and animal data point 
towards nitric oxide (NO) as a major regulator of vascular perfusion and matching of energy 
supply and demand (24,25,76,119,147,190). Nevertheless, considerable controversy 
persists with respect to its sources and mechanisms of action.  
 
Several reviews have covered modulation of energetic metabolism by nitric oxide 
(33,219,232). In this article we highlight the crucial role NO plays in achieving 
cardiocirculatory homeostasis during acute hypoxia through both vasodilation and metabolic 
suppression, and the various mechanisms through which NO production is enhanced. We 
identify a key position for nitric oxide in the body’s adaptation to an acute energy supply-
demand mismatch. 
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Bioenergetic reactions and the role of oxygen 
 
Living cells constantly perform work to maintain their structures, synthesize cellular 
components, generate transmembrane ionic gradients, and to undertake their physiologic 
roles. As most of these metabolic processes are thermodynamically unfavorable, they are 
coupled directly or indirectly to the hydrolysis of ATP to provide the necessary free energy. 
ATP supply is maintained through mitochondrial and cytoplasmic reactions that proceed with 
and without the need for oxygen (32). With its net yield of 2 moles ATP per mole of glucose, 
glycolysis is generally insufficient to maintain steady-state energy levels in most cell types. 
Exceptionally, some cells (e.g. erythrocytes) rely solely upon glycolytic production of ATP. 
Many immune cells use glucose and glutamine as their primary fuel sources, although 
ketone bodies and fatty acids can be used to a lesser degree (168). Glucose appears to be 
particularly necessary for cell survival, size, activation and cytokine production. Resting 
lymphocytes have low-energy needs and derive most of their ATP from oxidative 
phosphorylation; switching to the activated state requires a dramatic increase in metabolism, 
which is mainly derived from rapid upregulation of glycolysis (80). Organs also vary in their 
predominant energy substrate. Whereas most utilize carbohydrates as their major energy 
source, some (e.g. cardiomyocytes) predominantly use fatty acids.  Notably, this preference 
can change with a reduction in oxygen availability.  
 
Pathways leading to ATP synthesis have been extensively studied (145). Briefly, the 
glycolytic end-product pyruvate, and fatty acids enter mitochondria where they are 
metabolized to acetyl CoA. This enters the tricarboxylic acid (Krebs’) cycle whereby 
oxidation reactions directly produce ATP equivalents and electron donors. Electrons are 
transported down the respiratory chain, generating a proton gradient across the inner 
mitochondrial membrane, which serves as the driving force for phosphorylation of ADP to 
ATP. By comparison with glycolysis, 1 mole of glucose liberates approximately 30 moles of 
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ATP. Oxygen is crucially required as the terminal electron acceptor by the last complex of 
the chain, cytochrome c oxidase (CcO, complex IV) (44). In the steady state, approximately 
90% of total body O2 consumption occurs within mitochondria (204), and is primarily directed 
towards oxidative phosphorylation. A constant O2 supply is thus critical for continued cell 
function and survival. When compromised (e.g. supply reduced and/or demand excessively 
increased), a state of metabolic crisis ensues (231) with potential activation of cell death 
pathways. 
 
Oxygen and nutrients required by mammalian cells to support metabolism cannot be directly 
obtained in sufficient quantity by diffusion alone. From an evolutionary perspective, this 
limitation was resolved by the development of a cardio-respiratory system whose activity is 
closely regulated such that, in the steady state, ventilation delivers oxygen to the alveolar 
capillaries at the same rate of delivery by the vasculature to the tissues, and of consumption 
by metabolic processes within the tissues (233). The quantity of oxygen delivered to tissues 
(DO2) depends on arterial oxygen content (mainly carried by hemoglobin) and cardiac output. 
Regulation and distribution of cardiac output is driven by regional O2 consumption (VO2) that 
proceeds at a rate set by tissue metabolic activity. If DO2 is reduced, VO2 is initially maintained 
by increased O2 extraction. If delivery is reduced further, a critical point is reached below which 
tissue extraction cannot increase any further, leading to a fall in VO2 (212). Several 
complementary macro- and microcirculatory mechanisms act to prevent the onset of tissue 
hypoxia in the face of a reduced DO2. These include a redistribution of blood flow to ‘vital’ 
organs, increased recruitment of perfused microvessels to facilitate O2 availability (233), as 
depicted in figure 1 and, as discussed later, a decrease in tissue utilization (metabolism) 
 
Sensing hypoxia 
How eukaryotic cells sense reductions in pO2 remains contentious. Five main mechanisms 
have been proposed (132) based on, respectively, heme-based proteins, O2-sensitive ion 
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channels, AMP kinase, NADPH oxidase and mitochondria. Thus, hypoxia may be detected 
by an allosteric shift towards a deoxy- configuration in proteins capable of reversibly binding 
O2 at a heme site, or by ion channels affected by local pO2, as has been shown in carotid 
body cells where hypoxia can inhibit a specific K+ current. Reduced O2 levels increase the 
AMP:ATP ratio thus, at sufficient magnitude, AMP-activated protein kinases (AMPK) are 
induced, modulating cellular metabolism at various levels via target protein phosphorylation. 
With molecular O2, NADPH oxidase or other non-mitochondrial enzymes such as xanthine 
oxidase or flavin-containing dehydrogenases generate superoxide (O2
.-), providing a second 
messenger that may regulate cellular activity through redox modifications. Finally, increased 
mitochondrial reactive oxygen species (ROS) production during hypoxia may result in 
mitochondrial O2 sensing through changes in redox state of the electron transport chain, 
though without necessarily affecting respiration (50,72,96). Mitochondria may play a critical 
role in oxygen sensing. This model has been controversial as previous studies, which mainly 
relied on pharmacologic tools, produced conflicting reports (223). However, recent studies 
using genetic and biochemical approaches have provided evidence for a role of 
mitochondrial reactive oxygen species (mROS) in oxygen sensing and hypoxia-inducible 
transcription factor-1 (HIF-1) activation (38). Indeed, blocking superoxide anion production 
by suppressing the Rieske iron-sulfur protein of complex III impairs HIF-1 induction by 
hypoxia, whereas hydrogen peroxide or agents that produce ROS activate HIF-1 during 
normoxia (95). These data indicate that mitochondria can function as O2 sensors and 
stabilize HIF-1α during hypoxia by releasing ROS to the cytosol (96). 
  
The hypoxia-inducible transcription factor 1 (HIF-1) pathway is central to the body’s innate 
response to the stressful condition of hypoxia. HIF is a heterodimer composed of α and β 
subunits that induces expression of multiple genes that promote adaptation and survival 
(214). The β subunit is constitutively expressed, while  subunit expression is tightly 
regulated by the local oxygen tension through the action of prolyl hydroxylase (PHD). When 
O2 tension falls below a critical threshold, proline residues cannot be hydroxylated. This 
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prevents ubiquitination, allowing the -subunit to accumulate and hetero-dimerize with HIF-
1β. The heterodimer can then bind to specific DNA regions within the nucleus, exerting its 
regulatory activities. The PHDs are considered effective O2 sensors in their own right as their 
Km values for oxygen are above atmospheric O2 concentrations (110). This allows small 
changes in O2 supply to affect the enzyme’s activity. 
 
For responses to occur, a decrease in PO2 must be detected by an O2 sensor that activates 
signalling pathways triggering functional responses. In general, adaptation to acute changes 
in O2 concentration (lasting from seconds to minutes) principally occur as a result of 
alterations of pre-existing proteins (e.g. involving phosphorylation or changes in redox state), 
whereas chronic changes (lasting from minutes to hours or longer) mainly occur through 
altered gene expression. 
 
Responding to hypoxia 
 (a) Transcriptomic 
Given oxygen’s essential role in cellular metabolism, a wide array of responses has evolved 
to cope with situations of oxygen supply-demand mismatch. Functional adaptation occurs at 
systemic, tissue and cellular levels, ultimately leading to a new phenotype that enhances the 
likelihood of survival (211). Such adaptation depends both on the modulation of activity of 
various enzymatic systems by metabolic messengers (e.g. pH, phosphate potential, redox 
potential), and on altered gene transcription with increased expression of genes encoding, 
for example, growth factors (e.g. VEGF, PDGF-β), cytokines (e.g. IL-1, IL-8), endothelin and 
adhesion molecules (e.g. VCAM-1, ICAM-1).  
 
The AMP kinase (AMPK) system is a well-conserved pathway for maintaining the balance 
between energy production and utilization (103). Triggered by an increase in AMP:ATP ratio, 
this system switches on an energy-preserving phenotype, both rapidly through 
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phosphorylating metabolic enzymes, and by a longer-term adaptation through regulating 
gene expression via phosphorylation of transcription factors and co-activators. AMPK targets 
include carbohydrate homeostasis, lipid metabolism, protein synthesis, mitochondrial 
biogenesis, cell signalling, proliferation, gene expression and transmembrane ion transport 
(128). 
 
Responses to hypoxia that involve induction or repression of gene expression are mainly 
mediated by HIF-1 (214). Three isoforms of HIF have been characterized, of which HIF-1α 
and HIF-2α are the most structurally similar and best studied. HIF-3 can be found as 
multiple splice variants, some of which can even inhibit activity of HIF-1 and HIF-2 (169). 
While HIF-1 is expressed ubiquitously in all cells, the other isoforms are only selectively 
expressed in certain tissues, such as vascular endothelium, lungs and kidney. Activation of 
HIF-1 and HIF-2 can regulate expression of many other genes induced by hypoxia, such as 
vascular endothelial growth factor (VEGF), a potent angiogenic factor that contributes to 
long-term adaptation to hypoxia through new blood vessel formation (130). However, each 
HIF isoform may have their unique targets offering different adaptive pathways to hypoxia 
(160); HIF-1 preferentially induces genes coding for the glycolytic pathway whereas HIF-2 is 
involved in regulation of genes important for cell cycle progression and induction of 
erythropoietin (161). The two HIF isoforms also have distinct and somewhat opposing roles 
to NO regulation in macrophages. While HIF-1 promotes iNOS expression and increases NO 
production, HIF-2 promotes arginase expression, reducing the amount of arginine available 
for NO synthesis (229). This may offer a balancing regulatory mechanism for NO 
homeostasis.  
  
Apart from O2 tension many other factors govern HIF stability, including microRNAs and  
post-translational modifications such as acetylation (91). In addition to O2, PHDs require 
Fe2+, 2-oxoglutarate and ascorbate to exert their activity, but may be inhibited by NO, Krebs’ 
Umbrello – page 9 
cycle intermediates and reactive oxygen species (126). To date, >200 HIF gene targets have 
been identified, including those encoding for proteins involved in angiogenesis, energy 
metabolism, erythropoiesis, cell proliferation and viability, vascular remodelling, and 
vasomotor responses (214).  
 
MicroRNAs, specific small, non-coding RNA sequences, also appear to be involved in the 
hypoxic response (140). These 19- to 24-ribonucleotide sequences, once transferred to the 
cytoplasm, inhibit target gene expression by translational repression and/or mRNA 
degradation. A common characteristic of the different microRNAs involved in hypoxic 
signalling is their dependence upon HIF (141). HIF may thus be the main modulator of the 
hypoxic response, either through direct gene induction, or by indirect microRNA-mediated 
gene repression (140). On the other hand, microRNAs may act as positive and negative 
feedback regulators of HIF-mediated responses (106). miR-210 is consistently upregulated 
in hypoxia and may play a central role in hypoxic signalling by modulating factors implicated 
in various pathways, e.g. downregulating expression of different components of the 
mitochondrial electron transport chain and the Krebs’ cycle, interfering with membrane 
trafficking, modulating migration and adhesion, differentiation and cell cycle (67).  
 
b) Hemodynamic effects  
At the systemic level, adaptation to hypoxemia affects many systems although the most 
evident changes involve the cardiocirculatory system. This response is composed of 
essentially unopposed local vasodilation in the heart and brain, and of a balance between 
the competing effects of locally-induced vasodilation and reflex chemoreceptor-sensed, 
sympathetic-mediated vasoconstriction in other tissues, e.g. kidney and skeletal muscle 
(206). This response pattern attempts to maintain an adequate O2 supply-demand ratio, 
compensating for any reduction in arterial O2 content, while preserving arterial perfusion 
pressure. Over 130 years ago, Roy and Brown recognized that interrupting tissue perfusion 
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produced a local, non neurally-mediated increase in blood flow, and that blood vessels could 
vary their diameter independently in response to local metabolic needs (208). Indeed, the 
main hemodynamic effect of hypoxia is systemic vasodilation with increases in cardiac 
output and heart rate, and redistribution of regional perfusion with increased coronary, 
carotid and hepatic and decreased renal blood flow. The sympathetic nervous system is 
activated with increased catecholamine levels but a reduced response to exogenous 
vasopressors (55,98,104,156,194,206,207).  Increases in forearm blood flow, a reduced 
vasomotor reflex and a reduced response to exogenous norepinephrine and angiotensin 
were noted in healthy volunteers made hypoxemic (104).  
c) Respiratory  
Haldane noted how hypoxia induced a rapid, shallow type of breathing in humans (101). The 
predominant ventilatory response is an increase in respiratory rate with a rise in bronchiolar 
tone (127), a response mainly mediated via hypoxemia-responsive peripheral 
chemoreceptors in the carotid and aortic bodies. 
d) Renal and endocrine  
Hypoxemia redistributes blood flow away from the kidney which, in response, increases 
blood volume via an antidiuretic and sodium-sparing effect (20,183). In volunteers breathing 
10.5% O2, blood pressure fell by 10% and urine output by 30% (109), yet vasopressin and 
cortisol levels significantly increased while urine osmolality more than doubled.  
e) Metabolic 
Mammalian cells undergo multiple adaptive modifications of metabolism in response to 
changes in O2 availability (184,215). Some organs with high metabolic demand (e.g. 
muscle, liver, brain, heart) cope with the initial energy imbalance through glycogenolysis, 
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phosphocreatine dephosphorylation and the adenylate kinase reaction (4). Moreover, a 
switch in fuel selection from lipid to carbohydrate oxidation optimizes the rate of ATP 
production by taking advantage of the higher ATP yield per mole of O2 consumed (94,113). 
ATP produced from fatty acid oxidation is strictly dependent upon the presence of oxygen. 
In contrast, glucose-derived ATP originates both from oxygen-dependent glycolysis and on 
glucose oxidation. During hypoxia, both fatty acid and glucose oxidation decrease, thereby 
increasing the importance of glycolytic-derived ATP which, in most cell types, only plays a 
minor role in normoxic conditions (182). However, in order to regenerate NAD+, pyruvate 
produced from glycolysis is converted to lactate rather than being utilized within the 
mitochondria, a process that ultimately depends on the presence of O2 as the terminal 
electron acceptor. Moreover, hydrogen ions. generated by the hydrolysis of glycolytic-
derived ATP, accumulate as these are not taken up by the mitochondria, and will eventually 
result in a fall in intracellular pH (210). Hypoxia, besides causing a critical reduction of 
oxygen availability for oxidative phosphorylation, also affects other mitochondrial processes 
including a decrease in Complex I-dependent respiration, and reversal of the direction of 
operation of the F0F1-ATPase (Complex V). This latter effect converts mitochondria into 
major ATP consumers as they attempt to restore and maintain membrane potential to 
prevent increased mitochondrial permeability transition and cell death (68). 
 
During hypoxia, expression and activity of carbohydrate transporters, and of enzymes 
involved in glycogenolysis and glycolysis are increased (215), while pyruvate 
dehydrogenase activity is inhibited (188). The net effect is a shunting of pyruvate away from 
mitochondria and an increase in glucose availability and glycolytic flux - the ‘Pasteur effect’. 
Hypoxia also realigns the subunit composition of cytochrome c oxidase (CcO), improving 
the efficiency of respiration (82). Furthermore, accumulation of the glycolytic intermediate, 
fructose 1,6-biphosphate, directly inhibits mitochondrial respiration (69), again linking an 
increase in glycolytic flux to decreases in O2 consumption. 
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Further adaptation to hypoxia is achieved through metabolic suppression, measured as a 
decrease in mitochondrial O2 consumption during hypoxia. This oxygen conformance  
(111) is recognized, at least to some extent, in human heart and in hepatocytes. It begins at 
partial pressures of O2 above the critical level at which diffusion limitation into the 
mitochondria affects oxidative phosphorylation (31). In addition, a reallocation of cellular 
energy between essential and non-essential ATP-demanding processes provides further 
defense against the energy mismatch. ATP-consuming processes are arranged in a 
hierarchy, with processes less critical for cell survival being first sacrificed (30). This is 
mainly achieved at the level of the two principal ATP consumers: ion pumps and protein 
synthesis. Hypoxia reversibly suppresses Na+/K+ ATPase activity and inhibits mRNA 
translation through multiple mechanisms (244). Indeed, a modified phenotype for adaptive 
hypoxia tolerance is expressed in indigenous highlander human populations (Quechuas, 
Sherpas and Tibetans), whereby improved coupling between ATP demand and supply 
pathways protects against imbalances due to environmental O2 limitation (112). Similarly, 
NO was increased in lowlanders acclimatizing to altitude; this was associated with changes 
in microcirculatory blood flow which increased local tissue oxygen delivery, in agreement 
with an adaptative role in hypoxia (147). 
Nitric oxide synthesis and metabolism  
a) Production by nitric oxide synthases 
A large proportion of NO synthesis occurs through the L-arginine-NO pathway (177), one of 
the main metabolic pathways for arginine (246) (as depicted in figure 2). With these 
reactions, the semi-essential amino acid L-arginine is metabolized to NO and L-citrulline by 
a family of nitric oxide synthases (NOS) (135). These enzymes are dimers formed by two 
monomers consisting of a flavin-containing reductase domain and a heme-containing 
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oxygenase domain. The NO synthesis reaction requires the presence of two oxygen 
molecules plus NADPH, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and 
tetrahydrobiopterin as coenzymes/cofactors (29). NOS may be ‘uncoupled’ in the absence 
(or reduced availability) of either L-arginine or tetrahydrobiopterin, or in the presence of the 
endogenous NOS inhibitor, asymmetric dimethylarginine (ADMA) (227,239). Here, electrons 
flowing from the reductase to the oxygenase domain are diverted to molecular O2 rather than 
to L-arginine, eventually resulting in production of superoxide rather than NO (239,247). 
Three isoforms of NOS have been characterized (135). The endothelial (eNOS) and 
neuronal (nNOS) isoforms are constitutively expressed. Although initially isolated in vascular 
endothelium and the nervous system, they have since been found in skeletal muscle, lung 
and liver and, recently, an eNOS-like NO producing machinery has been described in 
erythrocytes (134). These constitutive isoforms can rapidly increase NO production. In 
health, they play important regulatory roles in neurotransmission and the cardiovascular 
system. Production of the inducible isoform (iNOS) depends on transcription; several hours 
are needed to reach peak activity. Its gene transcript increases on exposure to pro-
inflammatory cytokines and bacterial products. In general, iNOS generates larger 
(nanomolar vs picomolar) quantities of NO compared to its constitutive isoforms (5). This is 
related to the amount of protein expressed. The existence of a specific mitochondrial variant 
of NOS (mtNOS) has been claimed (88,142). However, others challenge its existence as no 
specific mtNOS sequence has yet been found in mitochondrial DNA, nor has any pathway 
enabling NOS protein transport into these organelles been identified, nor could it be found 
when specifically sought (142). 
This picture is further complicated by the ability of most cells to express multiple isoforms in 
different compartments. In the heart, for instance, nNOS is expressed within the 
sarcoplasmic reticulum and its activation increases contractility, whereas eNOS is confined 
to the caveolae and inhibits β-adrenoreceptor-mediated increases in contractility (16). 
Moreover, constitutively expressed NOS can be modulated by post-translational 
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modifications and phosphorylation (216) or be induced (135), while iNOS may be 
constitutively expressed at low levels in some tissues (189). 
b) Dietary nitrite/nitrate intake 
Though traditionally considered as inert oxidative end-products, nitrate (NO3
-) and nitrite 
(NO2
-) may play an important role in NO homeostasis (164). Diet is a major source of NO3
- 
with particularly high levels in leafy green vegetables. An average serving of beetroot 
contains more nitrate than is endogenously generated per day from NO generated by all 
three NOS isoforms combined. Once absorbed, most nitrate is ultimately excreted in urine. 
However, up to 25% is taken up by salivary glands and concentrated in the saliva where it 
reaches levels 10-fold higher than in plasma. Facultative anerobe bacteria within the oral 
cavity then reduce it to nitrite while using it as an alternative electron acceptor to O2 during 
respiration (165). Nitrite-rich saliva is then swallowed where, within the acidic milieu of the 
gastric lumen, NO2
- is rapidly protonated to nitrous acid that further decomposes to NO. This 
is termed the “nitrate-nitrite-nitric oxide pathway” (166) (figure 3). 
Orally administered nitrate or nitrite can modulate the endogenous NO system in various 
physiologic and pathophysiologic conditions (41,241,249). Significant increases in plasma 
NO3
- and NO2
- levels were measured in human volunteers after beetroot juice ingestion, with 
lowering of arterial BP by about 10 mmHg. This was prevented by interrupting the 
enterosalivary circulation through non-swallowing of saliva (241), or by selective suppression 
of the oral microflora with an antiseptic mouthwash (193). 
c)  Generation by other pathways:  
(i) Systemic nitrite reduction 
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Endogenously-formed or dietary nitrite in blood and tissues may be recycled to form NO-like 
bioactive molecules (Figure 3). In a human forearm blood flow study (90), Gladwin et al 
found that of the various plasma NO-related species, only NO2
- had a significant arterial-
venous gradient, indicating a degree of consumption during circulatory transit, and thus 
suggestive of possible bioactivity. This gradient markedly increased with exercise and 
inhibition of regional NO synthesis, suggesting that NO2
- is a plasma carrier of NO 
bioequivalents that are peripherally converted into bioactive NO. However, these results 
could not be replicated by Lauer et al (144) who reported no vasodilatory effect following 
intra-arterial administration of NaNO2 into healthy volunteers. This may relate to a shorter 
duration of nitrite infusion, or the need for nitrite to undergo metabolic conversion before 
becoming vasoactive. A careful comparison of the route of administration, the concentration 
and total dose of nitrite is needed to better understand its role (45). 
Various possible in vivo pathways by which nitrite is reduced to NO have been investigated 
(figure 4). Nitrite can form NO non-enzymatically under acidic and/or ischemic conditions 
(251). Using 15N-labelled nitrite to identify the source of NO, and enzyme inhibitors to 
exclude other pathways, NO generation was explained by a reaction of spontaneous 
disproportionation; however, the in vivo relevance of this pathway remains uncertain. 
Dedicated nitrite reductases are present in bacteria, but are lacking in humans. Nonetheless, 
certain mammalian enzymes show some nitrite reductase activity beyond their normal 
physiologic function. As an alternative to non-enzymatic reduction, proteins from the heme-
globin family (89) or from pterin-based molybdenum enzymes (149) may catalyze the NO2
--
reductase reaction to NO. An in vitro reaction of NO2
- with human deoxyhemoglobin forms 
NO and methemoglobin while an intra-arterial nitrite infusion produces, after several 
circulation times, a vasodilatory effect in healthy volunteers (60). Myoglobin, both in the 
heart and vasculature(105,185), also has significant NO2
--reductase activity, as do heme 
protein-containing enzymes such as the mitochondrial electron transport chain cytochromes 
(17,49,138), the cytochrome P450 family of microsomal heme proteins (151), and aldehyde 
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dehydrogenase (ALDH2), a mitochondrial enzyme involved in ethanol inactivation that has 
also been linked to the bioactivation of organic nitrates (13,51). Even eNOS and soluble 
guanylate cyclase (sGC), being heme-based enzymes, may have possible nitrite reductase 
activity, thereby offering an important alternative source of NO outside the conventional L-
arginine pathway (8,87).  
 
Given that Hb is an effective scavenger of NO, the possibility of a heme-independent 
pathway of NO synthesis from nitrite merits consideration as the in vivo relevance of nitrite 
reduction by heme-based enzymes may be challenged by the need for the newly 
synthesized NO to escape from this scavenging. The two most studied NO2
--reducing 
molybdenum-based enzymes are xanthine oxidoreductase (XOR) and aldehyde oxidase 
(149). The former plays a critical role in purine and pyrimidine catabolism, catalyzing 
oxidation of hypoxanthine to xanthine, and xanthine to uric acid. As it also reduces O2 to 
H2O2 and O2




- to NO under anerobic conditions; this can be blocked by 
the XOR-inhibitor, oxypurinol (152). Similarly, aldehyde oxidase, a cytosolic enzyme 
involved in biotransformation of drugs and xenobiotics, also has significant in vitro NO2
--
reductase activity (150).  
(ii) Release from pre-formed storage pools  
Attempting to solve the apparent paradox of the NO scavenging process being too rapid and 
effective to allow this short half-life molecule to exert its physiologic effects, it has been 
suggested that, depending on the oxygenation state of Hb, NO may either react with oxyHb 
to be oxidized to NO3
-, or can bind to the deoxygenated form to generate a nitrosyl-adduct 
(NO-Hb) that subsequently reacts with thiol groups to produce S-nitrosohemoglobin (SNO-
Hb) (121,191,225). SNO-Hb is more stable and has a longer half-life than NO, and its 
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administration can evoke a hypotensive response suggesting it acts as both carrier and 
donor of NO bioequivalents (figure 3). 
Other reservoirs of potential nitric oxide bioactivity include S-nitrosoalbumin (224), tissue 
nitrite, S-nitrosothiols (RSNO), N-nitrosamines (RNNO), and dinitrosyl iron complexes 
(DNIC). Their concentrations vary in different pathophysiologic states, typically showing 
marked elevation compared to basal levels in acute inflammation and reduction in the more 
chronic setting. Although little is known about their in vivo relevance, they may act as 
signalling molecules or storage forms of NO (43,73,237). Similar NO storage forms are 
found in other compartments such as the vascular wall (203). 
Regardless of location, all these compounds may be activated to release NO under certain 
conditions, and to contribute to the body pool of NO-related metabolites. Opinion still 
remains divided as to the in vivo importance of these mechanisms (90,118,198). A 
mitochondria-targeted S-nitrosothiol was recently shown to selectively induce NO production 
and S-nitrosylation (addition of an NO+ group to a protein thiol to form a nitrosothiol) at the 
mitochondrial level, producing vascular relaxation of pre-contracted aortic rings and 
protecting against ischemia-reperfusion (197). Molecules able to enhance trans-nitrosation 
reactions, transferring NO from one cysteine residue to another, constitute an emerging area 
of research in the field of drug design (86). 
d) NO metabolism 
The in vivo fate of NO is highly complex; several catabolic pathways exist (figure 5), with 
varying relevance in different body compartments (27,131). In vitro, NO rapidly reacts with 
O2 to form nitrogen dioxide (NO2). In the presence of NO at low concentration, the latter 
reacts with water to form equal amounts of nitrite and nitrate. At higher NO concentrations, 
NO2 reacts with another NO molecule to form dinitrogen trioxide (N2O3), which hydrolyses to 
form nitrite. In plasma, in the presence of O2, the principal reaction is formation of NO2
-  
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(115). Whether this is through autoxidation of NO, reaction with the plasma multi-copper 
oxidase ceruloplasmin (220), or oxidation by the mitochondrial cytochrome c oxidase in 
vascular cells is currently unclear (192,218,230). The situation differs in whole blood where 
the relatively high amount of oxyHb favours biotransformation of NO to NO3
- with 
concomitant formation of methemoglobin (27). This Hb reaction is considered by some as 
the primary catabolic process responsible for NO removal (107,124). A similar reaction with 
oxymyoglobin (to generate metmyoglobin and NO3
-) has been recently proposed as a crucial 
regulatory step of NO inactivation in muscle (40,79). However, other studies have shown 
that this reaction only takes place in conditions of excess NO (192).  
NO can also react with superoxide to produce peroxynitrite (ONOO-). The rapidity of this 
reaction, some 3-4-fold faster than O2
.- dismutation by superoxide dismutase, makes ONOO- 
formation a major potential disposal pathway of NO reactivity (92), though this does depend 
on the rate of tissue superoxide production. ONOO- itself may trigger oxidation or nitration 
reactions with various cellular targets modulating their biological activities, and is eventually 
converted into nitrate or nitrite (228). 
Nitrate and nitrite were long considered stable end-products of NO catabolism, however both 
are now recognized to be subject to further biotransformation (78,131,226). Highly reactive 
NO by-products (reactive nitrogen species) can react with protein thiol (-SH) groups to form 
S-nitrosothiols such as S-nitrosoalbumin, S-nitrosoglutathione and S-nitroso-hemoglobin 
(131), or with amines to generate N-nitrosamines. The physiologic significance of RNNOs is 
presently unknown, but concentrations change rapidly in response to an acute oxygen 
shortage (43).  NO itself can directly react with metals to generate metal nitrosyls, e.g. NO-
Hb. In addition to nitrosation, RSNOs may also be produced by oxidative nitrosylation. This 
reaction is mediated by generation of thiyl radicals (RS.) that may be derived from interaction 
of thiols with oxidants such as peroxynitrite (43). NO metabolism changes under hypoxic 
conditions, with greater production of metal nitrosyls, RSNOs and RNNOs (180). Some of 
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these products share some of the biologic properties of NO (226) and may possess the 
important biological functions of storing and transporting NO. Moreover, S-nitrosylation of 
thiol groups is a widespread post-translational redox-based protein modification. Similar to 
phosphorlyation, this exerts control over many protein classes in various physiologic and 
pathophysiologic conditions (108,157). 
e) Half-life of NO  
The process of NO transfer to its target remains incompletely understood. NO has high 
reactivity and a very short half-life, with measured blood levels being too low to likely exert 
any physiologically relevant effect (159). From in vitro studies, the half-life ranges from as 
little as 10-6 seconds to as much as 11.5 seconds (100). Mathematical modelling estimates 
an in vivo half-life of about 2 ms (158). Such a short half-life plus the rapid intravascular 
scavenging of NO has to be reconciled with the prominent autocrine and paracrine roles this 
molecule is believed to play in cellular physiology. Liao et al (154) proposed the existence of 
intravascular erythrocyte-free zones generated by blood flow that may increase the NO half-
life by several orders of magnitude due to reduced local NO scavenging, thus allowing the 
molecule to exert its biologic functions. Another possibility is the concept of stored NO 
bioactivity (66,221), as outlined above.  
To summarize, referring to the half-life of free NO may no longer be relevant given the 
rapidity of its transformation and interchange between different metabolites, many of which 
are longer lived than the parent molecule. A more complex system appears to be in place, in 
which the short half-life of NO itself is important in limiting the action of the molecule to its 
site of formation and to enable local signalling (autocrine and paracrine levels), while 
downstream biotransformation reactions make economical use of the NO produced as well 
as contributing to distant signalling (endocrine level). 
Nitric oxide and cardiovascular homeostasis 
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a) Nitric oxide as a regulator of vascular homeostasis  
NO is a core physiologic regulator of many cardiovascular processes, including platelet 
aggregation and adhesion, myocardial contractility, vascular permeability and tone 
(187,243). NO is essential for both global regulation and regional distribution of blood flow 
and pressure. Dysregulation of the NO system thus likely plays a fundamental role in many 
pathophysiologic conditions ranging from essential hypertension and atherosclerosis to the 
hypotension seen in acute shock states (243).   
Nitric oxide is a key contributor to new vessel formation: in endothelial cells, VEGF induced 
NO production via eNOS that, in turn, mediated angiogenesis (83). iNOS-derived NO may 
also have a role in angiogenesis (178). Besides being an effector of VEGF activation, NO 
also enhances growth factor synthesis in numerous cell types, mimicking the classical 
hypoxic stimulus (71). Thus, NO appears to act both as an upstream and a downstream 
mediator of VEGF-dependent angiogenesis. 
b) Mechanisms underlying the vasodilatory action of NO 
NO regulates blood pressure and flow through its effects on vascular smooth muscle tone. 
The shear stress generated by flowing blood against the endothelial surface triggers 
production of NO both basally (114), and in response to mechanostimulation (222). This 
increase in NO production is nonlinear with respect to shear stress (14). Of note, laminar 
blood flow (which increases shear stress) increases NO production whereas disturbed flow 
(causing low and oscillating shear stress) inhibits release of NO and fails to upregulate NOS 
(58). 
Being small and lipophilic, NO rapidly diffuses across membranes to reach vascular smooth 
muscle cells. Its main mechanism of action is mediated by nitrosylation of the heme-iron 
within sGC, leading to increased synthesis of cyclic GMP (cGMP) (243). This, in turn, 
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activates protein kinases that modulate myosin light chain kinase and phosphatase 
activities, resulting in less phosphorylation of myosin and, eventually, vasorelaxation (143). 
NO can also cause vasodilation via cGMP-mediated opening of calcium-sensitive (KCa) (10) 
and ATP-sensitive (KATP) (179) potassium channels. When these ion channels open, the 
outward efflux of potassium hyperpolarizes the plasma membrane, reducing vascular tone. 
NO also activates KATP and KCa channels in a cGMP-independent manner through direct S-
nitrosylation (28,129). NO may contribute to the regulation of intracellular free Ca2+ levels, 
either via cGMP-dependent inhibition of calcium influx through L-type Ca2+ channels (23), 
and/or via increased Ca2+ removal from the cytoplasm. The latter can occur by accelerating 
the Na+/Ca2+ exchanger (84), or by increasing sequestration into intracellular stores via the 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (2,56). This effect may be important as 
the constitutive isoforms of NOS are calcium-calmodulin-regulated (216). An increase in 
intracellular Ca2+ activates calmodulin leading to NO synthesis. Thus, it could be postulated 
that reduced intracellular levels of free calcium resulting from increased NO levels could 
reduce the amount of iNOS-generated NO, contributing to the fine tuning of NO levels. 
(figure 6) 
In health, eNOS mediates most of the hemodynamic actions of NO, contributing to blood 
flow regulation between different vascular beds according to their varying metabolic needs 
(177,243). NO derived from iNOS is traditionally considered to be primarily responsible for 
the vascular hyporeactivity and hypotension seen in inflammatory states (235). However, 
emerging data indicate an important role for nNOS-derived NO in basal microvascular tone 
regulation while eNOS-derived NO regulates changes in tone in response to agonists or 
shear stress (171). This suggests a potentially independent regulation of basal and 
stimulated blood flow.  
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Hypoxic vasodilation to improve coupling of oxygen delivery and utilization 
(a) Evidence for the involvement of NO  
Under hypoxemic conditions, a vasodilatory response occurs, augmenting blood flow in an 
attempt to maintain O2 delivery. Given its importance in the regulation of cardiovascular 
homeostasis, NO likely plays a key role. An association between NO and hypoxic 
vasodilation was first described in 1989 (196). This response was endothelium-dependent 
and significantly reduced by administration of oxyHb, acting as a potent NO scavenger. Ten-
fold higher levels of circulating NO products were found in residents of the Tibetan plateau 
compared to sea-level dwellers (76). This was associated with increased resting forearm 
blood flow suggesting an adaptive role that offsets the O2 lack caused by high altitude. In 
volunteers hypoxemia-induced increases in forearm blood flow were blocked by the non-
specific NOS inhibitor, L-NMMA (24). In awake sheep, hypoxemia-induced increases in 
cerebral blood flow and falls in cerebral vascular resistance were reversed by the sGC 
inhibitor, methylene blue (119). 
 
(b) Alternative theories 
Apart from its role as an energy source for cellular metabolic activity, ATP has important 
signaling characteristics, particularly in situations of reduced energy supply such as hypoxia. 
ATP release occurs in all major cell types (162), including endothelial cells, vascular smooth 
muscle cells and circulating red blood cells. In the blood vessel lumen, ATP levels increase 
during hypoxia (21) or conditions of increased shear stress (26). Precise mechanisms 
responsible for release are, at present, incompletely understood. Ellsworth et al have 
postulated a key role for the red blood cell (RBC) in sensing hypoxia (74) and modulating 
vascular tone via active release of ATP (75). Blood flow is significantly augmented, either 
through direct purinergic signaling or by inducing synthesis of vasoactive metabolites such 
as NO. These pathways do appear to intersect and interact with each other; indeed, NO can 
inhibit ATP release from RBCs (181) while nitrite enhances erythrocyte ATP synthesis and 
release during hypoxia (46). 
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(c) NO and control of metabolism 
In tandem with its role in hypoxic vasodilation, NO has potent inhibitory effects upon cellular 
metabolism that are significantly enhanced under hypoxic conditions (53,59). NO potently 
and reversibly reduces mitochondrial membrane potential (213) by competing with O2 at CcO 
(34). As less competition occurs in the presence of hypoxia, after an initial rapid (albeit 
reversible) inhibition of this enzyme, a potentially irreversible inhibition of Complex I occurs 
through nitrosylation and nitration that is also accelerated by hypoxia (52,81). For 
nitrosothiols and peroxynitrite to interact with Complex I, prior transition of the enzyme from 
its active (A) to its deactive (D) state is necessary, as only the D-form is susceptible to 
inactivation by these agents. Transition of Complex I from A to D preferentially occurs during 
hypoxia (85). This process may initially confer some degree of protection, reducing the 
amount of free radicals produced upon re-oxygenation, but may also initiate 
pathophysiological modifications of mitochondrial activity. Taken together, under conditions 
of reduced O2 availability NO mediates an important compensatory response through both 
enhancing supply and suppressing metabolic demand (figure 6). 
 
Other important effects of NO on intermediary metabolism are mediated through ONOO--
dependent activation of the AMPK system, or by direct nitrosation of critical thiols of target 
enzymes (122). The link between NO and the AMPK system involves different levels of 
regulation; for example, silencing of AMPK caused a decrease in cellular eNOS content 
(57). In particular, NO can limit energy-consuming anabolic processes such as hepatic 
gluconeogenesis and glycogen synthesis while inducing energy-producing catabolic 
pathways via increased expression of transmembrane carbohydrate transporters and a 
higher glycolytic flux (7,153). Over a longer time-scale, NO stimulates biogenesis of 
functionally active mitochondria (54). NO may also be an important modulator of the 
adaptive response to hypoxia; by redistributing O2 within cellular compartments and 
between neighbouring cells and interfering with the stabilization process of HIF-1, it 
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allows fine-tuning of cellular metabolism (99). Altered levels of NO and ROS likely impinge 
upon oxygen-sensing pathways. In a variety of cell types, NO stabilized HIF-1 protein and 
provoked HIF-1 target gene expression under normoxia (36). Whether this is due to NO 
itself or to a reactive intermediate, and whether or not the mechanism is cGMP-dependent 
is under active investigation (37). It does appear that the ability of NO to stabilize HIF-1 
depends to some extent on the formation of co-signals, such as, for instance, superoxide 
and the consequent production of peroxynitrite. 
 
Notwithstanding the above findings, some authors reported no impact of NO modulation on 
whole body (63) or myocardial (136) oxygen consumption. By contrast, others did find a 
modulating effect on whole body oxygen consumption (217). The negative studies used 
non-selective NOS inhibition but did not entertain the possibility that NO may be generated 
by alternate pathways such as nitrite reduction or release from RSNO. Moreover, the lack 
of effect after administering the NO donor sodium nitroprusside, or authentic NO, may be 
explained by the potent scavenging properties of haemoglobin and myoglobin. 
Conceivably, the effect of NO on oxygen delivery and consumption may be tissue-specific. 
In the brain, NO synergized with hypoxia to induce necrotic death via CcO inhibition in both 
neurons (120) and glia (170). NO-mediated inhibition of CcO may thus induce an adaptive 
state of reduced O2 consumption compensated for by increased glycolytic flux, or it may 
lead to a critical reduction in ATP production and cell death. The overall impact likely 
depends on the relative contribution of each process; this is turn depends on the extent 
and rate of metabolic perturbation and, perhaps, the cell type affected. 
 
(d) NO and microRNAs 
The interplay between NO and microRNA signalling is intriguing. Such cross-talk may 
connect a very fast and ubiquitous signalling pathway for the acute response to hypoxia 
with the master regulator of chronic hypoxia. This was recently demonstrated in studies of 
the mechanisms of ischemic or hypoxic myocardial preconditioning (209).  miR-21, a 
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microRNA induced in vascular tissue by shear stress, increased NO availability through 
phosphorylation of eNOS (242). Conversely, a NO donor modulated production of miR-21 
and other microRNAs, thereby regulating smooth muscle cell contraction (137). Brief bursts 
of myocardial ischemia induced miR-1, miR-21 and miR-24; this, in turn, induced eNOS 
mRNA and upregulated eNOS protein, whereas no effect was seen on iNOS. This miR-
induced, eNOS-derived NO had cardioprotective effects against ischemia-reperfusion 
injury, possibly by restoring the O2 supply/demand balance (248). 
  
Very recently, another aspect of miR-mediated regulation of the NO pathway was 
discovered: a well-known paradox of iNOS-derived NO is that cytokine stimulation can 
upregulate iNOS gene expression >2000-fold but, in some tissues, the increase in NO 
levels was far less (167). miR-939 decreased cytokine-induced iNOS protein expression 
but with no effect on iNOS mRNA levels or stability, thereby contributing to post-
translational silencing through direct binding to the iNOS gene (93).  Similarly, increases in 
miR-146a activity inhibited of LPS-induced iNOS expression and NO production (64). 
These findings have been interpreted as an endogenous protective mechanism against the 
untoward consequences of prolonged iNOS overexpression. 
 
(e) NO and the renin-angiotensin system  
The renin-angiotensin system (RAS) is an important regulator of blood flow and pressure 
through renal, vascular and central mechanisms (97). The classical pathway involves 
binding of angiotensin II to the angiotensin II type 1 receptor (AT1), to exert inotropic and 
vasocontrictor actions through increasing intracellular free calcium. The type 2 receptor 
(AT2) serves to counterbalance activation of the AT1 pathway; one of the main pathways 
associated with AT2 activation is stimulation of NO production (47). AT2 activation 
significantly attenuated mitochondrial respiration, and this was reversed by the NOS inhibitor 
L-NAME (1). 
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(f) NO levels in hypoxia: balance of synthesis and metabolism 
The NO concentration at any given location represents the balance between local 
synthesis and metabolism/elimination. During hypoxic vasodilation, the rise in NO levels 
may derive from increased production via NOS isoforms, and/or increased NO synthesis 
from alternate pathways (e.g. nitrite reduction or RSNO release), and/or reduced 
elimination, e.g. by conversion to NO2
- or NO3
- (figure 7). An alternative (or perhaps 
concurrent) mechanism is of vasodilation due to other factors such as ATP release by 
RBCs; the resulting increase in shear stress increases NO production which then further 
enhances the vasodilatory response. 
 
(i) Does hypoxia increase NO production by NOS? 
NOS-related NO production increases during hypoxia. In dogs, NOS inhibition reversed 
hypoxemia-induced tachycardia, hypotension and increases in cardiac output (12), findings 
subsequently replicated in human volunteer studies (25,48,236). However, NOS inhibition 
also accentuated the hypoxia-induced rise in pulmonary vascular resistance (25).  
 
Given the rapidity (seconds to minutes) of hypoxic vasodilation, the initial increase in NO 
synthesis is likely to be primarily mediated by a constitutively expressed NOS isoform. O2 
regulates transcription of eNOS (11) and possibly nNOS (19). With prolonged hypoxia, NO 
levels progressively rise; in an ex vivo macrophage model iNOS mRNA was detected after 
1.5 hours of hypoxia (9). HIF-1 may influence with iNOS expression under hypoxic 
conditions (125). In some cell types such as macrophages, hypoxia cannot by itself induce 
iNOS expression, whereas the synergistic combination of hypoxia and interferon-γ was a 
potent inducer (172). In other cell types (e.g. cardiomyocytes), hypoxic activation of the 
HIF-1 pathway could upregulate iNOS expression by itself, though this was significantly 
amplified with interleukin-1β (125). In pulmonary artery endothelial cells, hypoxia alone did 
not induce iNOS expression, but it significantly modulated cytokine induction of the gene, 
prolonging the half-life of cytokine-induced iNOS mRNA from 6 to 17 hours (250). 
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However, hypoxia itself can induce expression of inflammatory cytokines (133) which then 
can activate iNOS. Thus, a more complex scenario probably exists in vivo with co-
participation of all three isoforms. 
 
The oxygen atom in NO and citrulline is derived from molecular oxygen, regardless of 
synthesis by constitutive or inducible isoforms of NOS (146). Hypoxia could attenuate the 
NO component of endothelium-dependent vascular relaxation, likely due to decreased NO 
production secondary to oxygen depletion (123,200). The apparent Km values for oxygen 
were 17, 6 and 5 mmHg for neuronal, endothelial and inducible isoforms of NOS 
respectively(201). These values are close to the Km values of other enzymes that utilize O2 
as a substrate, e.g. CcO. As the neuronal isoform shows a higher Km value for O2, it is 
thus more sensitive to the prevailing oxygen concentration. 
 
Despite its apparent simplicity, the likelihood that hypoxic vasodilatation can be 
predominantly explained by de novo NOS synthesis presents at least three major 
contradictions. Given that NOS-derived NO synthesis requires molecular O2, it seems 
counter-intuitive in situations of O2 lack to record an increase in NO production. Indeed, 
some in vitro experiments report reductions in eNOS mRNA expression and decreased 
NO production during hypoxia (155,200,245). These results conflict with those cited 
above and may relate to the degree of hypoxia (or anoxia) experienced, the varying O2 
sensitivity of the different cells/tissues studied, and/or a possible biphasic nature of 
events relating to the time course of the overall response (e.g. feedback inhibition of 
NOS expression secondary to an acute initial increase in NO availability, followed by a 
gradual increase in expression as hypoxia persists). Nevertheless, these studies raise 
important concerns regarding the true significance of NOS-derived NO in hypoxia. 
Secondly, increased arginase activity during hypoxia is a well-known process 
(139,163), and this reduces the amount of substrate available for the reaction by NOS.  
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A more complex regulation of NO synthesis from NOS may exist during hypoxia. In a 
rodent model of chronic hypoxia, exposure to 10% O2 significantly increased pulmonary 
eNOS expression, in addition to an increase in ADMA concentration, reduced DDAH, 
(the enzyme responsible for ADMA disposal) and reduced tissue nitrate/nitrite (NOx) 
concentrations (175). They postulated that hypoxia reduces DDAH activity that, in turn, 
increases ADMA concentrations that leads to eNOS inhibition and reduced synthesis of 
NO. Finally, in several studies NOS inhibition could only partially reverse hypoxic 
vasodilation, thus other mechanisms must be implicated (35,148). 
 
 (ii) Does hypoxia increase NO release from SNO-Hb and other NO storage forms? 
Stamler’s theory for hypoxic vasodilation demands a central role for erythrocytes in 
matching blood flow to local metabolic demands. The affinity of hemoglobin for NO is 
similar to that for O2, i.e. high in the relaxed deoxygenated state, and low in the tense 
oxygenated state (225). A cysteine residue on the hemoglobin β-chain reacts with NO to 
form a nitroso-adduct (SNO-Hb) that acts as a carrier of NO bioactivity. Erythrocytes thus 
act as O2 sensors to control regional blood flow. Erythrocytes could rapidly relax thoracic 
aortic rings from both rabbits and mice under hypoxic but not normoxic conditions, though 
this relaxation could be inhibited by either depletion of SNO-Hb or sGC blockade (70).  
 
(iii) Does hypoxia increase reduction of nitrite to NO? 
The findings of an increased concentration of NO during hypoxic vasodilation, full reversal 
of these hemodynamic effects by sGC inhibition but not by NOS blockade, a strict O2 
dependence of the NOS reaction, and the possibility that NO2
- can be converted to NO, 
particularly under acidic conditions, suggest that nitrite itself may act as a NO-equivalent 
donor during hypoxia (3,176). cGMP-dependent nitrite vasodilation and the rise in 
measured NO have been interpreted as evidence for the involvement of a NO-mediated 
relaxation, rather than a direct NO2
- effect. Intravenous infusion of sodium nitrite (1 
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µmol/min) into healthy volunteers increased forearm blood flow and reduced pulmonary 
artery pressure only under hypoxemic (12% O2) conditions, but was not related simply to 
an increase in plasma nitrite concentration (116). These data are consistent with a direct 
extravascular metabolism of NO2
- to NO to exert hypoxia-associated bioactivity. Whether 
endogenous nitrite concentrations are sufficient to cause similar hemodynamic effects 
remains uncertain at present. 
 
Of the many different mammalian molecules with nitrite reductase activity (figure 4), the 
most extensively studied is hemoglobin. Addition of erythrocytes induced a left shift in the 
vasodilatory dose-response curve and cGMP accumulation in response to nitrite but only 
under hypoxic conditions (61). This could be inhibited by the NO scavenger, C-PTIO. Thus, 
NO2
- exerted a higher vasodilatory effect when deoxygenated Hb was present, again 
emphasizing the role of NO-dependent mechanisms in hypoxic vasodilation.  
 
Hemoglobin may be an important physiologic O2 sensor that can modulate vascular tone 
by (i) scavenging excess NO and (ii) increasing local blood flow through NO generation 
from nitrite when O2 content is reduced. This theory remains controversial because of the 
avid NO-scavenging properties of hemoglobin to the point that it has been argued that this 
phenomenon has minimal, if any, in vivo relevance (6). The Gladwin group countered with 
a recent ex vivo study using rat vascular rings (117) wherein the balance between the NO-
scavenging and generating properties of hemoglobin was specifically targeted during both 
normoxia and hypoxia. They found that nitrite displays a particular interaction with 
deoxyhemoglobin that promotes vasodilation despite its scavenging properties.  
 
Myoglobin can also act as a nitrite reductase, with NO being produced in vitro by reaction 
between NO2
- and myoglobin (199). This conversion was significantly reduced in cardiac 
tissue taken from a myoglobin knockout mouse model but restored by adding exogenous 
myoglobin. Under hypoxic conditions in vitro (238) and ex vivo (240) eNOS also displays 
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nitrite reductase activity. As for the pterin-based enzymes, both xanthine oxidoreductase 
(174,240) and aldehyde oxidase (195) are sources of NO2
- reduction, particularly during co-
existing hypoxia and acidosis.  
 
The apparently conflicting theories of NO2
- reduction and S-nitrosothiols acting as non-NOS 
dependent sources of NO, and as regulators of local blood flow under both physiologic and 
hypoxic/ischemic conditions, may be reconciled (42,77). Under physiologic conditions, 
nitrite is not directly reduced to NO but rather modulates many signalling pathways, 
including sGC activation. It also induces post-translational modifications normally 
associated with NO, such as the formation of nitroso- and nitrosyl species (42). NO2
- may 
therefore exert its signalling functions directly, without the need for intermediary formation 
of free NO. Hypoxia markedly potentiates tissue NO production from NO2
- in a dose-
dependent manner (77). This occurs particularly in heart, liver and vascular tissue, with 
multiple heme, iron-sulfur cluster and molybdenum-based reductases distributed among 
distinct subcellular compartments acting in a multifactorial and cooperative manner to 
catalyze the reaction. Acute hypoxia also reduces NO2
- concentrations yet enhances 
formation of NO metabolites such as RSNOs and RNNOs in an NO-independent manner. 
This suggests a pathway that generates bioactive NO metabolites directly from NO2
-. In this 
paradigm, conversion of NO2
- to NO and the storage of NO bioactivity as RSNOs may both 
be constituents of a more complex regulatory mechanism of interaction of multiple NO-
related species. The differences in oxygen dependence of nitrite reductase activity in 
tissues (exponential) versus red blood cells (optimum around the p50) suggest that the 
regulatory range of the latter may operate at intermediate levels of hypoxia whereas the 
former predominates as PO2 drops further.
 
 
(iv) Does hypoxia reduce NO metabolism by cytochrome c oxidase? 
Moncada’s group suggested that the hypoxia-induced increase in NO is due to reduced 
elimination rather than increased production (186,234). Plausibility has been tested in a 
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computational model of brain O2 transport and metabolism (205), with description of the 
kinetic parameters that link decreased NO metabolism by CcO with low O2 concentrations. 
They showed in L-arginine-supplemented iNOS-overexpressing cells that the capacity of 
CcO to metabolize NO was diminished at low O2 tensions, and that this correlated with 
both the enzyme’s redox state and consequent sGC activation. The same effect was seen 
when the redox state was altered by cyanide rather than hypoxia. Whereas NOS inhibition 
was effective at reducing NO levels, NO2
- administration had no effect on NO release at 
any O2 tension (186,234). NO production was also similar at all O2 tensions, regardless of 
whether CcO was oxidized or reduced (234). They thus concluded that CcO (in its oxidized 
state) constantly inactivates NO, thus regulating its intracellular concentration. However, in 
the reduced state seen in hypoxia, impaired inactivation would account for the increase in 
NO. This leads to local vasodilatation with improvements in oxygen delivery and a 
concurrent reduction in oxygen consumption due to direct inhibition of CcO, thereby 
facilitating the matching of delivery to needs under hypoxic conditions. Further studies are 
needed to demonstrate the in vivo relevance of these findings. 
 
Conclusions 
Hypoxic vasodilatation is an adaptive response that involves elevations in local NO 
concentrations in response to an acute reduction in arterial PO2. This both increases blood 
flow to restore O2 delivery and also modulates local metabolic requirements, thus attempting 
to re-balance an acute oxygen supply-demand mismatch. Several mechanisms are 
implicated (Figure 7) including increased NO synthesis from NOS, increased reduction of 
nitrite to NO by heme- or pterin-based enzymes, increased release of NO from NO storage 
forms, and reduced deactivation by mitochondrial cytochrome c oxidase. Many of these 
mechanisms have been shown either in in vitro/ex vivo conditions or by utilization of 
pharmacologic dosing regimens, so the question remains as to their in vivo 
(patho)physiologic relevance. While tissue hypoxia can result from decreases in arterial PO2, 
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blood flow or hemoglobin concentration (15), the adaptive mechanism for each form of 
hypoxia need not be identical. A recent animal study (62) demonstrated that NOS inhibition 
did not blunt the increase in myocardial blood flow during acute normovolemic hemodilution, 
and suggested, at least in this form of tissue hypoxia, that NO did not mediate vasodilation. 
Further work is needed to fully elucidate the multiple and varied roles of NO under hypoxic 
conditions, and to integrate these into an overall picture. 
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Glossary of non-standard Abbreviations and Acronyms  
ADMA: asymmetric dimethylarginine;  ALDH2: aldehyde dehydrogenase;  AMPK: AMP-
activated protein kinases;  AO: aldehyde oxidase;  CcO: cytochrome c oxidase;  cGMP: 
cyclic GMP;  DO2: oxygen delivery;  Hb: haemoglobin;  HIF-1: hypoxia inducible factor-1;  
N2O3: dinitrogen tetroxide;  NO: nitric oxide;  NO2-: nitrate;  NO2: nitrogen dioxide;  NO3-: 
nitrate;  NOS: nitric oxide synthase;  O2.-: superoxide radical;  ONOO-: peroxynitrite;  PO2: 
partial pressure of oxygen;  RNNO: N-nitrosamines;  ROS: reactive oxygen species;  RSNO: 
S-nitrosothiols;  sGC: soluble guanylate cyclase;  SNO-Hb: S-nitrosohemoglobin;  VO2: 
oxygen consumption;  XOR: xanthine oxidoreductase 
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Figures and figure legends 
Figure 1. Oxygen supply-demand relationship.  
The relationship between oxygen delivery to cells and oxygen consumption is non-linear. 
Initial reduction in the amount of oxygen delivered are compensated by a series of adaptive 
mechanisms. If delivery is reduced further, a critical point is reached (DO2 crit) below which 
tissue extraction cannot increase any further, leading to a fall in consumption. Several 
complementary macro- and microcirculatory mechanisms act to prevent the onset of tissue 
hypoxia in the face of a reduced delivery, and many of them are mediated by nitric oxide. 
 
Figure 2. Metabolic pathways for arginine.  
Four major metabolic pathways for arginine exist: first, arginine is degraded to urea and 
ornithine by isoforms of the enzyme arginase. A large part of arginine is used for protein 
synthesis, and arginine is also involved in the biosynthesis of creatine. Another metabolic 
pathway of arginine is the synthesis of nitric oxide (NO) by endothelial, neuronal or inducible 
isoforms of the enzyme NO synthase (respectively, eNOS, nNOS and iNOS) with 
concomitant formation of citrulline. The NO synthesis reaction requires the presence of two 
oxygen molecules plus NADPH as coenzymes/cofactors, and proceeds with two steps, a 
first one in which the intermediate N(G)-hydroxy-L-arginine (N-OH-L-Arg) is formed, and a 
second one in which NO and citrulline are formed as products. 
 
Figure 3. Multiple pathways of NO synthesis. 
Nitric oxide (NO) synthesis occurs in blood and tissues through the classical L-arginine-NO 
pathway, where the semi-essential amino acid L-arginine is metabolized to NO and L-
citrulline by a family of nitric oxide synthases (NOS) that use oxygen as co-factor. 
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Endogenously-formed or dietary-derived nitrite in blood and tissues may be reduced to NO. 
Dedicated nitrite reductases are present in bacteria, but are lacking in humans. Nonetheless, 
certain mammalian enzymes under hypoxic conditions may show some nitrite reductase 
activity beyond their normal physiologic function, such as proteins from the heme-globin 
family or from pterin-based molybdenum enzymes. S-nitrosothiols (RSNO) are other 
circulating reservoirs and carriers of potential nitric oxide bioactivity. Their concentrations 
vary in different pathophysiologic states, and under hypoxic conditions they may be 
activated to release NO from their thiol (-SH) group. The most studied of such storage pool 
is hemoglobin (Hb): a cysteine residue on the β-chain may react with NO to form a nitroso-
adduct (SNO-Hb) that, under hypoxic conditions releases NO bioactivity.  Traditionally 
considered as inert oxidative end-products, dietary nitrate (NO3
-) and nitrite (NO2
-) contribute 
to NO homeostasis through the gastroenteric “nitrate-nitrite-nitric oxide pathway”. Once 
absorbed from the diet, a significant part of plasma NO3
- is concentrated in the saliva. 
Bacteria within the oral cavity then reduce it to nitrite. Nitrite-rich saliva is swallowed, and 
within the acidic milieu of the gastric lumen NO2
- is rapidly converted to NO. 
 
Figure 4. Enzymes with putative nitrite-reductase activity. 
Dedicated nitrite reductases are present in bacteria, but are lacking in humans. Nonetheless, 
certain mammalian enzymes show some nitrite reductase activity beyond their normal 
physiologic function. As an alternative to non-enzymatic reduction, proteins from the heme-
globin family (such as deoxygenated haemoglobin – HHb, and myoglobin – HMb, the 
mitochondrial cytochrome bc1 complex – CIII, cytochrome c oxidase – CcO, and cytochrome 
c – CytC, as well as aldehyde dehydrogenase – ALDH2, the endothelial isoform of NOS – 
eNOS, and soluble guanylate cyclase – sGC)  or from pterin-based molybdenum enzymes  ( 
such as xanthyne oxidoreductase – XOR, sulphide oxidase – SO and aldehyde oxidase – 
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AO) may all catalyze the NO2
--reductase reaction to NO, expecially under hypoxic 
conditions. 
 
Figure 5. Pathways of NO metabolism in normoxic conditions. 
NO rapidly reacts with molecular oxygen (O2) to form nitrogen dioxide (NO2). If NO is present 
at low concentration, the NO2 reacts with water to form equal amounts of nitrite and nitrate. 
At higher NO concentrations, NO2 reacts with another NO molecule to form dinitrogen 
trioxide (N2O3), which hydrolyses to form nitrite (NO2
-), or may dimerize to form dinitrogen 
tetraoxide (N2O4). In plasma, the principal fate of NO is formation of NO2
-, although the exact 
reaction is unclear (autoxidation, reaction with ceruloplasmin, or oxidation by the 
mitochondrial cytochrome c oxidase – CcO). In whole blood NO reacts with oxygenated 
hemoglobin (oxyHb) to form nitrate (NO3
-) with concomitant formation of methemoglobin 
(MetHb). A similar reaction with oxymyoglobin (oxyMb) happens in tissues.  NO can also 
react with superoxide (O2
.-) to produce peroxynitrite (ONOO-); the latter may directly trigger 
oxidation or nitration reactions with various cellular targets, and is eventually converted into 
nitrate or NO2. Highly reactive NO by-products (“reactive nitrogen oxide species”, i.e. ONOO
-
, NO2, N2O3, N2O4), possibly through the formation of nitrosonium equivalents (NO
+), can 
react with protein thiol (-SH) groups to form S-nitrosothiols (RSNOs), or with amines to 
generate N-nitrosamines (RNNOs). NO can also directly react with metals (Mex) to give 
metal nitrosyls (MexNO). In addition to nitrosation, RSNOs may also be produced by 
oxidative nitrosylation. 
 
Figure 6. Effects of increased NO levels during hypoxia in the balancing of oxygen 
supply and demand. 
Left panel (A). Metabolic and contractile state of an ideal cell during normoxic conditions. 
ATP supply is maintained through mitochondrial and cytoplasmic reactions. Glucose (Gluc) 
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is transported from the interstitium via GLUT carriers. The vast majority of pyruvate, the end-
product of glucose breakdown, enters the mitochondria after oxidation by the enzyme 
pyruvate dehydrogenase (PDH). Here, it is completely oxidized with reactions coupled to the 
synthesis of ATP. Oxygen (O2) is crucially required as the terminal electron acceptor of the 
respiratory chain, Cytochrome c Oxidase (CcO). A small part of the pyruvate is reduced to 
lactate by lactate dehydrogenase (LDH). In conditions of excess of substrate availability, 
glucose is stored as glycogen. The contractile state of the cell is maintained through cycling 
of myosin from a phosphorylated to a dephosphorylated state, via the enzymes myosin light 
chain kinase and phosphatase, respectively (MLCK and MLKP). 
Right panel (B). Adaptive modifications of metabolism and contractile state during hypoxia. 
The increased levels of exogenous or endogenously formed nitric oxide (NO) during hypoxia 
contribute to the adaptation to the energy supply-demand mismatch. NO reduces 
mitochondrial metabolic demand by competing with O2 at CcO. It also limits energy-
consuming anabolic processes such as glycogen synthesis and induces energy-producing 
catabolic pathways via the increased expression and activity of GLUT transporters, and of 
enzymes involved in glycogenolysis and glycolysis, while PDH activity is inhibited. The net 
effect is a shunting of pyruvate away from mitochondria and an increase in glucose 
availability and glycolytic flux. NO also activates the enzyme soluble guanylate cyclase 
(sGC), leading to increased synthesis of cyclic GMP (cGMP). This, in turn, modulates MLCK 
and MLCP activities, resulting in less phosphorylation of myosin and, eventually, 
vasorelaxation. NO can also cause vasodilation via cGMP-mediated opening of calcium-
sensitive (KCa) and ATP-sensitive (KATP) potassium channels. When these ion channels 
open, the outward efflux of K+ hyperpolarizes the plasma membrane, reducing vascular tone. 
NO may also activate those ion channels in a cGMP-independent manner through direct S-
nitrosylation of cysteine (SH) residues. Eventually, NO regulates the intracellular free Ca2+ 
concentration, either via a cGMP-dependent inhibition of calcium influx through L-type Ca2+ 
channels (LTC), and/or via an increased Ca2+ removal from the cytoplasm. The latter may 
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occur by accelerating the Na+/Ca2+ exchanger (SCE), or increasing the sequestration into 
intracellular stores via the sarcoplasmic/endoplasmic reticulum (SER). The net effects of an 
increase in NO levels are reduced consumption of oxygen, increased glycolytic ATP 
production, and vasodilation that increases the supply of oxygen and nutrients. Solid arrows 
indicate pathways induced by NO; dashed arrows indicate inhibition. 
 
Figure 7. Effects of hypoxia on NO metabolic pathways 
Possible mechanisms of increased NO levels under hypoxic conditions include: 1) increased 
production by NOS; 2) increased release from storage forms such as RSNO; 3) increased 
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